Since the first reports of the COVID-19 outbreak, our primary concern at Novartis has and continues to be the health and safety of our associates and patients globally. As COVID-19 continues to spread around the world, many countries are imposing community-based interventions to enhance social distancing, in an effort to help slow the spread of COVID-19.
Novartis is committed to doing our part to help slow the spread of the disease and has requested that all US-based associates work from home starting March 16 until at least April 3, 2020. We recognize that based on the nature of the work of some associates, it is not always feasible to work remotely - these associates will receive guidance specific to their role from their local leadership teams. We are asking our field-based associates to limit face-to-face interactions and are encouraging the use of virtual HCP interactions, while only engaging in business critical meetings necessary to ensure appropriate patient treatment and support with our medicines, continuity of supply, or care in a clinical trial setting where no viable alternative to a face-to-face meeting is available. We will continuously assess the situation and adapt accordingly.
As we enter into this new work environment, we are committed to making sure that our medicines are delivered to patients around the world, and while not all aspects of delivering medicines globally are in our control, we do not anticipate supply chain disruption at this time.